A recent proposal that calls for reducing the benefits of the 340B Drug Pricing Program to curb rapidly rising prescription drug costs is “misguided,” writes AHA Executive Vice President Tom Nickels in an AHASTAT blog post today. Responding to a recent opinion piece in the New England Journal of Medicine, Nickels said, “The 340B program is more important now than ever before as the prices of prescription drugs continue to skyrocket. Instead of trying to make changes to a program with a strong track record of increasing access to care for patients in vulnerable communities, policymakers should consider other solutions, such as requiring greater transparency on drug pricing and charity policies by drug companies, increased competition in the generic industry or other reasonable proposals.” For more on the 340B program, visit www.aha.org/protect340B.

Related News Articles

Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
A JAMA study published Aug. 18 found that plan design changes by Medicare Part D insurers, particularly for Medicare Advantage plans, following passage of the…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the…
Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…